Celldex Therapeutics
CLDX
30.43
-0.58
-1.85%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
30.43
-0.58
-1.85%
Live - 5344 symbols - heartbeat 19s ago
· 2026-10-08 06:17
Pre-market
30.24
-0.63%
After-hours
30.51
+0.26%
- Market cap
- 2.39B
- P/E (TTM)i
- -7.00
- P/Bi
- 3.34
- EPSi
- -3.90
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on CLDX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Buy
Avg price target
68.70 +125.8%
Price target rangecurrent 30.43
Low53.00
Avg68.70
High100.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | H.C. Wainwright | -- | BUY | 64.00 |
| 2026-10-03 | LifeSci Capital | -- | BUY | 64.00 |
| 2026-10-02 | H.C. Wainwright | -- | BUY | 64.00 |
| 2026-09-28 | LifeSci Capital | -- | BUY | 64.00 |
| 2026-09-26 | LifeSci Capital | -- | BUY | 56.00 |
| 2026-09-23 | CCORF | -- | BUY | 60.00 |
| 2026-09-23 | Wells Fargo | -- | BUY | 72.00 |
| 2026-09-23 | Morgan Stanley | -- | BUY | 57.00 |
| 2026-09-23 | Leerink Partners | -- | BUY | 88.00 |
| 2026-09-23 | H.C. Wainwright | -- | BUY | 64.00 |
| 2026-09-22 | Morgan Stanley | -- | BUY | 57.00 |
| 2026-09-22 | Stifel | -- | BUY | 68.00 |
| 2026-09-22 | Guggenheim | -- | BUY | 100.00 |
| 2026-09-22 | H.C. Wainwright | -- | BUY | 64.00 |
| 2026-09-22 | Barclays | -- | BUY | 53.00 |
| 2026-09-20 | LifeSci Capital | -- | BUY | 56.00 |
| 2026-09-10 | Morgan Stanley | -- | BUY | 50.00 |
| 2026-08-07 | LifeSci Capital | -- | BUY | 56.00 |
| 2026-08-07 | Morgan Stanley | -- | BUY | 46.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 42.00 |
| 2026-08-07 | Barclays | -- | BUY | 53.00 |
| 2026-08-06 | Cantor Fitzgerald | -- | BUY | 61.00 |
| 2026-08-06 | CCORF | -- | BUY | 60.00 |
| 2026-08-06 | Wells Fargo | -- | BUY | 72.00 |
| 2026-08-06 | Guggenheim | -- | BUY | 100.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Sell to Buy on 2026-04-20.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-20 | Barclays | SELL → BUY | 45.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2023/Q4 | 2024-02-26 | After close | ±16.09% | +5.83% (in line) |
| 2021/Q4 | 2022-02-28 | After close | ±17.30% | +5.62% (in line) |
| 2020/Q2 | 2020-08-06 | -- | ±33.39% | -4.87% (in line) |
| 2019/Q2 | 2019-08-07 | After close | -- | +2.31% |
| 2018/Q4 | 2019-03-07 | After close | -- | +10.87% |
| 2018/Q2 | 2018-08-08 | After close | -- | -6.76% |
| 2017/Q4 | 2018-03-07 | -- | -- | +11.34% |
| 2017/Q2 | 2017-08-08 | -- | -- | -1.17% |
| 2016/Q4 | 2017-03-14 | After close | -- | +3.33% |
| 2016/Q2 | 2016-08-08 | -- | -- | -3.00% |
| 2015/Q4 | 2016-02-25 | -- | -- | +0.58% |
| 2015/Q2 | 2015-08-10 | After close | -- | -20.56% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:17:29 · For reference only, not investment advice and not tailored to your situation.